RU2013124814A - HETEROCYCLIC DERIVATIVES OF DIAZENIUM DIOLATE - Google Patents

HETEROCYCLIC DERIVATIVES OF DIAZENIUM DIOLATE Download PDF

Info

Publication number
RU2013124814A
RU2013124814A RU2013124814/04A RU2013124814A RU2013124814A RU 2013124814 A RU2013124814 A RU 2013124814A RU 2013124814/04 A RU2013124814/04 A RU 2013124814/04A RU 2013124814 A RU2013124814 A RU 2013124814A RU 2013124814 A RU2013124814 A RU 2013124814A
Authority
RU
Russia
Prior art keywords
tert
diolate
butyl
diazen
methylamino
Prior art date
Application number
RU2013124814/04A
Other languages
Russian (ru)
Inventor
Амджад Али
Майкл Ман-Чу ЛО
Роберт К. Бейкер
Чжицян Го
Брент УАЙТХЕД
Тимоти Дж. ХЕНДЕРСОН
Эдвард МЕТЦГЕР
Линь ЯНЬ
Шриник К. ШАХ
Джеймс ДЕЛЛУРЕФИСИО
Цзюнь Ванг
Original Assignee
Мерк Шарп Энд Домэ Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп Энд Домэ Корп. filed Critical Мерк Шарп Энд Домэ Корп.
Publication of RU2013124814A publication Critical patent/RU2013124814A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

1. Соединение, имеющее формулу I:или его фармацевтически приемлемая соль, гдеX означает O или NR;Rозначает водород, -C(O)OCалкил или -C(O)OH, или вместе с Rобразует =O;Rозначает водород или вместе с Rобразует =O;Rи Rпредставляют собой независимо-Cалкил,-Cалкилен-OH,-Cалкилен-C(O)OH,-Cалкилен-O-C(O)Cалкил,-Cалкилен-арил или-CHCH=CH,или вместе с атомом азота, к которому они присоединены, образуют 4-7-членное гетероциклическое кольцо, содержащее один атом азота и 0 или 1 атом кислорода, где указанное кольцо является незамещенным или моно-, ди- или три-замещенным галогеном, -Cалкилом или группой Cалкил-OH;Rи R, которые присоединены к любому доступному атому углерода кольца, представляют собой независимоводород,-Cалкил,-C(O)OCалкил,-C(O)OH,арил,или Rи R6, когда они присоединены к одному и тому же атому углерода, вместе образуют =O;Rозначаетводород,-Cалкил,-Cалкилен-арил,-CалкиленC(O)O-Cалкил,-CалкиленC(O)OH,-CалкиленCF,-CN,-C(O)O-Cалкил,-C(O)Cалкил,-C(O)OCкарбоцикл,-C(O)CHF,-C(O)CHF,-C(O)CHOH,-C(O)арил,-C(O)CалкиленOHC(O)Cкарбоцикл,-C(O)NH,-C(O)NHCалкил,-C(O)NH-арил,-C(O)гетероцикл,-C(O)NHCкарбоцикл,-C(O)N(Cалкил)Cалкил,-C(O)NHSOарил,-SOCалкил,-SOCалкил,-SOCF,-SOарил,-SOгетероарил,арил,гетероарил,гетероцикл или-Cкарбоцикл;где арил, алкил, карбоцикл, гетероарил и гетероцикл являются незамещенными или замещены 1, 2, 3 или 4 группами, независимо выбранными из R, где Rозначает независимо -CN, галоген, CF, =O, -C(O)OCалкил, -O-Cалкил, -OCF, -Cалкил, гетероарил, -C(O)NHили -O-N=N(O)N(CH)(C(CH)),и его фармацевтически приемлемые соли.2. Соединение по п.1, имеющее формулу Iaили его фармацевтически приемлемая соль.3. Соединение по п.1, имеющее формулу Ibили его фармацевтически приемлемая соль.4. Соединение по п.1, где Rозначает водород, -C(O)OH или -C(O)OCH, или его фармацевтически приемлемая с1. The compound having the formula I: or a pharmaceutically acceptable salt thereof, where X is O or NR; R is hydrogen, —C (O) OC alkyl or —C (O) OH, or together with R forms = O; R is hydrogen or together with R forms = O; R and R are independently Ci-Ci, -Cialkylene-OH, -Cialkylene-C (O) OH, -Ci-alkylene-OC (O) Ci-alkyl, -Cialkylene-aryl or -CHCH = CH, or together with a nitrogen atom, to which they are attached form a 4-7 membered heterocyclic ring containing one nitrogen atom and 0 or 1 oxygen atom, wherein said ring is unsubstituted or mono-, di- or tri-substituted by halogen, -Calk sulphyl or a C1-6alkyl-OH group; R and R, which are attached to any available carbon atom of the ring, are independently hydrogen, —Calkyl, —C (O) OC alkyl, —C (O) OH, aryl, or R and R6 when attached to to the same carbon atom, together form = O; R is hydrogen, -Calkyl, -Calkylene-aryl, -CalkyleneC (O) O-Calkyl, -CalkyleneC (O) OH, -Calkylene CF, -CN, -C (O) O -Calkyl, -C (O) C1-6alkyl, -C (O) OC carbocyclic, -C (O) CHF, -C (O) CHF, -C (O) CHOH, -C (O) aryl, -C (O) Calkylene OHC (O) C carbocyclic, -C (O) NH, -C (O) NHC alkyl, -C (O) NH-aryl, -C (O) heterocycle, -C (O) NHC carbocyclic, -C (O) N ( C1-6alkyl) C1-6alkyl, -C (O) NHSOaryl, -SOCalkyl, -SOCalkyl, -SOCF, -SOryl, -SO heteroaryl, aryl, heteroaryl, het a cycloalkyl or -Carbocycle; where aryl, alkyl, carbocycle, heteroaryl and heterocycle are unsubstituted or substituted by 1, 2, 3 or 4 groups independently selected from R, where R is independently —CN, halogen, CF, = O, —C (O ) OC alkyl, —O — C1-6alkyl, —OCF, —Calkyl, heteroaryl, —C (O) NH or —ON = N (O) N (CH) (C (CH)), and pharmaceutically acceptable salts thereof. 2. A compound according to claim 1, having the formula Ia or a pharmaceutically acceptable salt thereof. A compound according to claim 1, having the formula Ib or a pharmaceutically acceptable salt thereof. The compound according to claim 1, where R is hydrogen, —C (O) OH or —C (O) OCH, or its pharmaceutically acceptable with

Claims (23)

1. Соединение, имеющее формулу I:1. The compound having the formula I:
Figure 00000001
Figure 00000001
 или его фармацевтически приемлемая соль, гдеor its pharmaceutically acceptable salt, where X означает O или NR7;X is O or NR 7 ; R1 означает водород, -C(O)OC1-6алкил или -C(O)OH, или вместе с R2 образует =O;R 1 means hydrogen, —C (O) OC 1-6 alkyl or —C (O) OH, or together with R 2 forms = O; R2 означает водород или вместе с R1 образует =O;R 2 means hydrogen or together with R 1 forms = O; R3 и R4 представляют собой независимоR 3 and R 4 are independently -C1-6алкил,-C 1-6 alkyl, -C1-6алкилен-OH,-C 1-6 alkylene-OH, -C1-6алкилен-C(O)OH,-C 1-6 alkylene-C (O) OH, -C1-6алкилен-O-C(O)C1-6алкил,-C 1-6 alkylene-OC (O) C 1-6 alkyl, -C1-6алкилен-арил или-C 1-6 alkylene-aryl or -CH2CH=CH2,-CH 2 CH = CH 2 , или вместе с атомом азота, к которому они присоединены, образуют 4-7-членное гетероциклическое кольцо, содержащее один атом азота и 0 или 1 атом кислорода, где указанное кольцо является незамещенным или моно-, ди- или три-замещенным галогеном, -C1-6алкилом или группой C1-6алкил-OH;or together with the nitrogen atom to which they are attached form a 4-7 membered heterocyclic ring containing one nitrogen atom and 0 or 1 oxygen atom, wherein said ring is unsubstituted or mono-, di- or tri-substituted halogen, -C 1-6 alkyl or a group C 1-6 alkyl-OH; R5 и R6, которые присоединены к любому доступному атому углерода кольца, представляют собой независимоR 5 and R 6 that are attached to any available ring carbon atom are independently водород,hydrogen, -C1-6алкил,-C 1-6 alkyl, -C(O)OC1-6алкил,-C (O) OC 1-6 alkyl, -C(O)OH,-C (O) OH, арил,aryl или R5 и R6, когда они присоединены к одному и тому же атому углерода, вместе образуют =O;or R 5 and R6, when attached to the same carbon atom, together form = O; R7 означаетR 7 means водород,hydrogen, -C1-6алкил,-C 1-6 alkyl, -C1-6алкилен-арил,-C 1-6 alkylene-aryl, -C1-6алкиленC(O)O-C1-6алкил,-C 1-6 alkylene; C (O) OC 1-6 alkyl; -C1-6алкиленC(O)OH,-C 1-6 alkylene C (O) OH, -C1-6алкиленCF3,-C 1-6 alkylene CF 3 , -CN,-CN, -C(O)O-C1-6алкил,-C (O) OC 1-6 alkyl, -C(O)C1-6алкил,-C (O) C 1-6 alkyl, -C(O)OC3-6карбоцикл,-C (O) OC 3-6 carbocycle, -C(O)CHF2,-C (O) CHF 2 , -C(O)CHF3,-C (O) CHF 3 , -C(O)CH2OH,-C (O) CH 2 OH, -C(O)арил,-C (O) aryl, -C(O)C1-6алкиленOHC(O)C3-6карбоцикл,-C (O) C 1-6 alkylene; OHC (O) C 3-6 carbocycle, -C(O)NH2,-C (O) NH 2 , -C(O)NHC1-6алкил,-C (O) NHC 1-6 alkyl, -C(O)NH-арил,-C (O) NH-aryl, -C(O)гетероцикл,-C (O) heterocycle, -C(O)NHC3-6карбоцикл,-C (O) NHC 3-6 carbocycle, -C(O)N(C1-6алкил)C1-6алкил,-C (O) N (C 1-6 alkyl) C 1-6 alkyl, -C(O)NHSO2арил,-C (O) NHSO 2 aryl, -SOC1-6алкил,-SOC 1-6 alkyl, -SO2C1-6алкил,-SO 2 C 1-6 alkyl, -SO2CF3,-SO 2 CF 3 , -SO2арил,-SO 2 aryl, -SO2гетероарил,-SO 2 heteroaryl, арил,aryl гетероарил,heteroaryl гетероцикл илиheterocycle or -C3-6карбоцикл;-C 3-6 carbocycle; где арил, алкил, карбоцикл, гетероарил и гетероцикл являются незамещенными или замещены 1, 2, 3 или 4 группами, независимо выбранными из R8, где R8 означает независимо -CN, галоген, CF3, =O, -C(O)OC1-6алкил, -O-C1-6алкил, -OCF3, -C1-6алкил, гетероарил, -C(O)NH2 или -O-N=N+(O-)N(CH3)(C(CH3)3),where aryl, alkyl, carbocycle, heteroaryl and heterocycle are unsubstituted or substituted by 1, 2, 3 or 4 groups independently selected from R 8 , where R 8 is independently —CN, halogen, CF 3 , = O, —C (O) OC 1-6 alkyl, -OC 1-6 alkyl, -OCF 3 , -C 1-6 alkyl, heteroaryl, -C (O) NH 2 or -ON = N + (O - ) N (CH 3 ) (C (CH 3 ) 3 ), и его фармацевтически приемлемые соли.and its pharmaceutically acceptable salts. 2. Соединение по п.1, имеющее формулу Ia2. The compound according to claim 1, having the formula Ia
Figure 00000002
Figure 00000002
Figure 00000003
Figure 00000003
 или его фармацевтически приемлемая соль.or a pharmaceutically acceptable salt thereof. 3. Соединение по п.1, имеющее формулу Ib3. The compound according to claim 1, having the formula Ib
Figure 00000004
Figure 00000004
Figure 00000005
Figure 00000005
 или его фармацевтически приемлемая соль.or a pharmaceutically acceptable salt thereof. 4. Соединение по п.1, где R1 означает водород, -C(O)OH или -C(O)OCH3, или его фармацевтически приемлемая соль.4. The compound according to claim 1, where R 1 means hydrogen, —C (O) OH or —C (O) OCH 3 , or a pharmaceutically acceptable salt thereof. 5. Соединение по п.1, где R2 означает водород, или его фармацевтически приемлемая соль.5. The compound according to claim 1, where R 2 means hydrogen, or its pharmaceutically acceptable salt. 6. Соединение по п.1, где R3 означает -CD2C1-5алкил, -C(CH3)3, -CH2CH3 или -CH(CH3)2.6. The compound according to claim 1, where R 3 means —CD 2 C 1-5 alkyl, —C (CH 3 ) 3 , —CH 2 CH 3 or —CH (CH 3 ) 2 . 7. Соединение по п.1, где R4 означает -CD2C1-5алкил, -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -CH2CH2-фенил, -CH2-фенил, -CD2CH3, -CH2CH2OH, -CH2C(O)OH, -CH2CH2OC(O)CH3 или -CH2CH=CH2,7. The compound according to claim 1, where R 4 means —CD 2 C 1-5 alkyl, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH 2 CH 2 CH 2 CH 3 , - CH 2 CH 2 -phenyl, -CH 2 -phenyl, -CD 2 CH 3 , -CH 2 CH 2 OH, -CH 2 C (O) OH, -CH 2 CH 2 OC (O) CH 3 or -CH 2 CH = CH 2 , или его фармацевтически приемлемая соль.or a pharmaceutically acceptable salt thereof. 8. Соединение по п.1, где R5 означает водород, -CH3, C(O)OCH3, -C(O)OH, фенил, или его фармацевтически приемлемая соль.8. The compound according to claim 1, where R 5 means hydrogen, —CH 3 , C (O) OCH 3 , —C (O) OH, phenyl, or a pharmaceutically acceptable salt thereof. 9. Соединение по п.1, где R6 означает водород или -CH3, или его фармацевтически приемлемая соль.9. The compound according to claim 1, where R 6 means hydrogen or —CH 3 , or a pharmaceutically acceptable salt thereof. 10. Соединение по п.1, где R5 и R6 присоединены к одному и тому же атому углерода и вместе образуют =O, или его фармацевтически приемлемая соль.10. The compound according to claim 1, where R 5 and R 6 are attached to the same carbon atom and together form = O, or a pharmaceutically acceptable salt thereof. 11. Соединение по п.1 или его фармацевтически приемлемая соль, где R7 означает водород, -CH3, -CH2CF3, -CH2C6H5, -CH(CH3)C6H5, -CH2C(O)OH, -CH2C(O)OCH3, -CH(CH3)C(O)OCH2CH3, -C(CH3)2C(O)OCH2CH3, -CH2CH(CH2CH3)2, -CH(CH2CH3)2, -C(CH3)2C6H5, -C(CH3)3, -CN, -CH2CH(CH3)2 или
Figure 00000006
11. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 7 is hydrogen, —CH 3 , —CH 2 CF 3 , —CH 2 C 6 H 5 , —CH (CH 3 ) C 6 H 5 , —CH 2 C (O) OH, -CH 2 C (O) OCH 3 , -CH (CH 3 ) C (O) OCH 2 CH 3 , -C (CH 3 ) 2 C (O) OCH 2 CH 3 , -CH 2 CH (CH 2 CH 3 ) 2 , -CH (CH 2 CH 3 ) 2 , -C (CH 3 ) 2 C 6 H 5 , -C (CH 3 ) 3 , -CN, -CH 2 CH (CH 3 ) 2 or
Figure 00000006
 12. Соединение по п.1 или его фармацевтически приемлемая соль, где R7 означает -C(O)OC(CH3)3, -C(O)CH3, -C(O)CF3, -C(O)OCH2CH3, -C(O)OC6H11, -C(O)CHF2, -C(O)C6H5, -C(O)CH2OH, -C(O)C3H5, -C(O)C(CH3)3, -C(O)NH2, -C(O)NHC(CH3)3, -C(O)NHC6H11, -C(O)N(CH3)C(CH3)3, -C(O)SC(CH3)3, -C(O)NHSO2C6H5,
Figure 00000007
12. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 7 is —C (O) OC (CH 3 ) 3 , —C (O) CH 3 , —C (O) CF 3 , —C (O) OCH 2 CH 3 , -C (O) OC 6 H 11 , -C (O) CHF 2 , -C (O) C 6 H 5 , -C (O) CH 2 OH, -C (O) C 3 H 5 , -C (O) C (CH 3 ) 3 , -C (O) NH 2 , -C (O) NHC (CH 3 ) 3 , -C (O) NHC 6 H 11 , -C (O) N (CH 3 ) C (CH 3 ) 3 , -C (O) SC (CH 3 ) 3 , -C (O) NHSO 2 C 6 H 5 ,
Figure 00000007
 13. Соединение по п.1 или его фармацевтически приемлемая соль, где R7 означает -SO2CH3, -SO2C6H5, -SO2C(CH3)3, -SOC(CH3)3, -SO2CF3,
Figure 00000008
13. The compound according to claim 1 or its pharmaceutically acceptable salt, where R 7 means —SO 2 CH 3 , —SO 2 C 6 H 5 , —SO 2 C (CH 3 ) 3 , —SOC (CH 3 ) 3 , - SO 2 CF 3 ,
Figure 00000008
 14. Соединение по п.1 или его фармацевтически приемлемая соль, где R7 означает -C6H5,14. The compound according to claim 1 or its pharmaceutically acceptable salt, where R 7 means -C 6 H 5 ,
Figure 00000009
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000012
 15. Соединение по п.1 или его фармацевтически приемлемая соль, где R7 означает15. The compound according to claim 1 or its pharmaceutically acceptable salt, where R 7 means
Figure 00000013
Figure 00000013
Figure 00000014
Figure 00000014
Figure 00000015
Figure 00000015
Figure 00000016
Figure 00000016
Figure 00000017
Figure 00000017
Figure 00000018
Figure 00000018
 16. Соединение по п.1 или его фармацевтически приемлемая соль, где R7 означает -C6H11 или -C5H9.16. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 7 is —C 6 H 11 or —C 5 H 9 . 17. Соединение по п.1, где R3 и R4 вместе с атомом N, к которому они присоединены, образуют 5- или 6-членное гетероциклическое кольцо, содержащее 1 атом N, причем кольцо является незамещенным или замещено группой -CH2OH.17. The compound according to claim 1, where R 3 and R 4 together with the N atom to which they are attached form a 5- or 6-membered heterocyclic ring containing 1 N atom, wherein the ring is unsubstituted or is substituted by the group —CH 2 OH . 18. Соединение по п.1, где R1 вместе с R2 образует =O.18. The compound according to claim 1, where R 1 together with R 2 forms = O. 19. Соединение по п.1, которое представляет собой19. The compound according to claim 1, which is a O2-[(3R)-1-(трет-бутоксикарбонил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butoxycarbonyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3S)-1-(трет-бутоксикарбонил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3S) -1- (tert-butoxycarbonyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(трет-бутоксикарбонил)пирролидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butoxycarbonyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(трет-бутоксикарбонил)пирролидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butoxycarbonyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(трет-бутоксикарбонил)пиперидин-4-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (tert-butoxycarbonyl) piperidin-4-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[1-(трет-бутоксикарбонил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (tert-butoxycarbonyl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(трет-бутоксикарбонил)пиперидин-4-ил] 1-(N,N-диэтиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (tert-butoxycarbonyl) piperidin-4-yl] 1- (N, N-diethylamino) diazen-1-yl-1,2-diolate, O2-[1-(трет-бутоксикарбонил)пиперидин-4-ил] 1-(N-трет-бутил-N-пропиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (tert-butoxycarbonyl) piperidin-4-yl] 1- (N-tert-butyl-N-propylamino) diazen-1-yl-1,2-diolate, O2-[1-(трет-бутоксикарбонил)пиперидин-4-ил] 1-(N-бутил-N-трет-бутиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (tert-butoxycarbonyl) piperidin-4-yl] 1- (N-butyl-N-tert-butylamino) diazen-1-yl-1,2-diolate, O2-[1-(трет-бутоксикарбонил)пиперидин-4-ил] 1-(N-трет-бутил-N-фенилэтиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (tert-butoxycarbonyl) piperidin-4-yl] 1- (N-tert-butyl-N-phenylethylamino) diazen-1-yl-1,2-diolate, O2-[1-(трет-бутоксикарбонил)пиперидин-4-ил] 1-[N-трет-бутил-N-(2'-гидроксиэтил)амино]диазен-1-ий-1,2-диолат,O 2 - [1- (tert-butoxycarbonyl) piperidin-4-yl] 1- [N-tert-butyl-N- (2'-hydroxyethyl) amino] diazene-1-yl-1,2-diolate, (±)-O2-[1-(трет-бутоксикарбонил)пиперидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,(±) -O 2 - [1- (tert-butoxycarbonyl) piperidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[1-(трет-бутоксикарбонил)азетидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (tert-butoxycarbonyl) azetidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[1-(трет-бутоксикарбонил)азетидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (tert-butoxycarbonyl) azetidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-пирролидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -pyrrolidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-(пиперидин-4-ил) 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - (piperidin-4-yl) 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(2-метилпропил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (2-methylpropyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-бензилпирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1-benzylpyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, (±)-O2-[(3R)-1-(1-фенилэтил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,(±) -O 2 - [(3R) -1- (1-phenylethyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(2-фенилпропан-2-ил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (2-phenylpropan-2-yl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-трет-бутилпирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1-tert-butylpyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-(1-метилпиперидин-4-ил) 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - (1-methylpiperidin-4-yl) 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(2,2,2-трифторэтил)пирролидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (2,2,2-trifluoroethyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(2,2,2-трифторэтил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (2,2,2-trifluoroethyl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-(1-бензилпиперидин-4-ил) 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - (1-benzylpiperidin-4-yl) 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, (±)-O2-[1-(1-фенилэтил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,(±) -O 2 - [1- (1-phenylethyl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-фенилпирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1-phenylpyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(3-цианофенил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (3-cyanophenyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-1-[3-(метоксикарбонил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -1- [3- (methoxycarbonyl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-1-[3-(трифторметил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -1- [3- (trifluoromethyl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-1-[3,5-бис(трифторметил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -1- [3,5-bis (trifluoromethyl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2- diolate O2-[(3R)-1-(1,3-тиазол-2-ил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (1,3-thiazol-2-yl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2- diolate O2-[1-(пиридин-2-ил)пиперидин-4-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (pyridin-2-yl) piperidin-4-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[1-(пиридин-3-ил)пиперидин-4-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (pyridin-3-yl) piperidin-4-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-(1-фенилпиперидин-4-ил) 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - (1-phenylpiperidin-4-yl) 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(3-цианофенил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (3-cyanophenyl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(6-цианопиридин-2-ил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (6-cyanopyridin-2-yl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(5-цианопиридин-2-ил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (5-cyanopyridin-2-yl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(4-цианопиридин-2-ил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (4-cyanopyridin-2-yl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(3-цианопиридин-2-ил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (3-cyanopyridin-2-yl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(трет-бутилкарбамоил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butylcarbamoyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(трет-бутилкарбамоил)пирролидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butylcarbamoyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-2-оксо-1-[4-(трифторметил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -2-oxo-1- [4- (trifluoromethyl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-y-1,2 diolate O2-[(3R)-1-ацетилпирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1-acetylpyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-(1-ацетилпиперидин-4-ил) 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - (1-acetylpiperidin-4-yl) 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(фенилкарбонил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (phenylcarbonyl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(гидроксиацетил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (hydroxyacetyl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(дифторацетил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (difluoroacetyl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(трифторацетил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (trifluoroacetyl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(фенилкарбонил)азетидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (phenylcarbonyl) azetidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(метилсульфонил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (methylsulfonyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(трет-бутилсульфонил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butylsulfonyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(2,2,2-трифторэтил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (2,2,2-trifluoroethyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-2-оксо-1-(2,2,2-трифторэтил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -2-oxo-1- (2,2,2-trifluoroethyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-y-1, 2-diolate, O2-[(3R)-5-оксо-1-(2,2,2-трифторэтил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -5-oxo-1- (2,2,2-trifluoroethyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-y-1, 2-diolate, (±)-O2-[1-(5-цианопиридин-2-ил)-2-оксопиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,(±) -O 2 - [1- (5-cyanopyridin-2-yl) -2-oxopiperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2 diolate O2-[(3S)-тетрагидрофуран-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3S) -tetrahydrofuran-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-тетрагидрофуран-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -tetrahydrofuran-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-(тетрагидро-2H-пиран-4-ил) 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - (tetrahydro-2H-pyran-4-yl) 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-(тетрагидро-2H-пиран-4-ил) 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - (tetrahydro-2H-pyran-4-yl) 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R,5S)-1-(трет-бутоксикарбонил)-5-(метоксикарбонил)пирролидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R, 5S) -1- (tert-butoxycarbonyl) -5- (methoxycarbonyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-y-1, 2-diolate, O2-[(3R,5S)-5-(метоксикарбонил)пирролидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R, 5S) -5- (methoxycarbonyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[(3R,5S)-5-карбоксипирролидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R, 5S) -5-carboxypyrrolidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(2-метокси-2-оксоэтил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (2-methoxy-2-oxoethyl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(карбоксиметил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (carboxymethyl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, (±)-O2-[1-(2,4-диоксо-1,3-тиазолидин-5-ил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,(±) -O 2 - [1- (2,4-dioxo-1,3-thiazolidin-5-yl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazene-1- Ii-1,2-diolate, O2-[1-(2,5-диоксоимидазолидин-4-ил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (2,5-dioxoimidazolidin-4-yl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(1-этокси-2-метил-1-оксопропан-2-ил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (1-ethoxy-2-methyl-1-oxopropan-2-yl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-y-1, 2-diolate, O2-[1-(5-карбамоилпиридин-2-ил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (5-carbamoylpyridin-2-yl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(5-цианопиразин-2-ил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (5-cyanopyrazin-2-yl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-1-[3-(1H-пиразол-1-ил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -1- [3- (1H-pyrazol-1-yl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-y-1 2-diolate O2-{(3R)-1-[3-(1H-1,2,4-триазол-1-ил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -1- [3- (1H-1,2,4-triazol-1-yl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazene -1-yl-1,2-diolate, O2-{(3R)-1-[3-(1H-1,2,3-триазол-1-ил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -1- [3- (1H-1,2,3-triazol-1-yl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazene -1-yl-1,2-diolate, O2-{(3R)-1-[3-(5-оксо-4,5-дигидро-1,2,4-оксадиазол-3-ил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -1- [3- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) phenyl] pyrrolidin-3-yl} 1- (N-tert -butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-1-[3-(5-оксо-4,5-дигидро-1,3,4-оксадиазол-2-ил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -1- [3- (5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl) phenyl] pyrrolidin-3-yl} 1- (N-tert -butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-цианопирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1-cyanopyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(5-метил-1,2,4-оксадиазол-3-ил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (5-methyl-1,2,4-oxadiazol-3-yl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazene-1- Ii-1,2-diolate, O2-[(3R)-1-(5-метил-4H-1,2,4-триазол-3-ил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (5-methyl-4H-1,2,4-triazol-3-yl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazene- 1st-1,2-diolate, O2-[(3R)-1-(5-оксо-4,5-дигидро-1,2,4-оксадиазол-3-ил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) pyrrolidin-3-yl] 1- (N-tert-butyl-N- methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(1H-тетразол-5-ил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (1H-tetrazol-5-yl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-карбамоилпирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1-carbamoylpyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-1-[трет-бутил(метил)карбамоил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -1- [tert-butyl (methyl) carbamoyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-1-[(3-цианофенил)карбамоил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -1 - [(3-cyanophenyl) carbamoyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, 1,1'-карбонилбис{O2-[(3R)-пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат},1,1'-carbonylbis {O 2 - [(3R) -pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate}, O2-[(3R)-1-(трет-бутилкарбамоил)пирролидин-3-ил] 1-(N-трет-бутил-N-пропиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butylcarbamoyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-propylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(трет-бутилкарбамоил)пирролидин-3-ил] 1-(N-трет-бутил-N-аллиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butylcarbamoyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-allylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(трет-бутилкарбамоил)пирролидин-3-ил] 1-[N-трет-бутил-N-(2'-гидроксиэтил)амино]диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butylcarbamoyl) pyrrolidin-3-yl] 1- [N-tert-butyl-N- (2'-hydroxyethyl) amino] diazen-1-y-1,2- diolate O2-[(3R)-1-(трет-бутилкарбамоил)пирролидин-3-ил] 1-[N-трет-бутил-N-(карбоксиметил)амино]диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butylcarbamoyl) pyrrolidin-3-yl] 1- [N-tert-butyl-N- (carboxymethyl) amino] diazen-1-yl-1,2-diolate, O2-[(3R)-1-(трет-бутилкарбамоил)пирролидин-3-ил] 1-(N-бензил-N-изопропиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butylcarbamoyl) pyrrolidin-3-yl] 1- (N-benzyl-N-isopropylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(трет-бутилкарбамоил)пирролидин-3-ил] 1-(N-бензил-N-бутиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butylcarbamoyl) pyrrolidin-3-yl] 1- (N-benzyl-N-butylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(трет-бутилкарбамоил)пирролидин-3-ил] 1-(пирролидин-1-ил)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butylcarbamoyl) pyrrolidin-3-yl] 1- (pyrrolidin-1-yl) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(трет-бутилкарбамоил)пирролидин-3-ил] 1-(пиперидин-1-ил)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butylcarbamoyl) pyrrolidin-3-yl] 1- (piperidin-1-yl) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(трет-бутилкарбамоил)пирролидин-3-ил] 1-[2-(гидроксиметил)пиперидин-1-ил]диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (tert-butylcarbamoyl) pyrrolidin-3-yl] 1- [2- (hydroxymethyl) piperidin-1-yl] diazen-1-yl-1,2-diolate, O2-[(3R)-1-(2-этилбутил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (2-ethylbutyl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(пентан-3-ил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (pentan-3-yl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(гептан-4-ил)пирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (heptan-4-yl) pyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-циклопентилпирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1-cyclopentylpyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-циклогексилпирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1-cyclohexylpyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[1-(2-этилбутил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (2-ethylbutyl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[1-(пентан-3-ил)пиперидин-4-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [1- (pentan-3-yl) piperidin-4-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-(1-циклопентилпиперидин-4-ил) 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - (1-cyclopentylpiperidin-4-yl) 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-(1-циклогексилпиперидин-4-ил) 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - (1-cyclohexylpiperidin-4-yl) 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-2-оксо-1-[5-(трифторметил)пиридин-2-ил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -2-oxo-1- [5- (trifluoromethyl) pyridin-2-yl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-I -1,2-diolate, O2-[(3R)-1-(3-метоксифенил)-2-оксопирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (3-methoxyphenyl) -2-oxopyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-2-оксо-1-[3-(трифторметил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -2-oxo-1- [3- (trifluoromethyl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-y-1,2 diolate O2-{(3R)-1-[3,5-бис(трифторметил)фенил]-2-оксопирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -1- [3,5-bis (trifluoromethyl) phenyl] -2-oxopyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-y-1 2-diolate O2-[(3R)-1-(3-цианофенил)-2-оксопирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (3-cyanophenyl) -2-oxopyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-2-оксопирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -2-oxopyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-бензил-2-оксопирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1-benzyl-2-oxopyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-2-оксо-1-[3-(трифторметокси)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -2-oxo-1- [3- (trifluoromethoxy) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-y-1,2 diolate O2-[(3R)-1-(3-хлорфенил)-2-оксопирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (3-chlorophenyl) -2-oxopyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-2-оксо-1-[3-(пропан-2-ил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -2-oxo-1- [3- (propan-2-yl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-I -1,2-diolate, O2-{(3R)-2-оксо-1-[6-(трифторметил)пиридин-3-ил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -2-oxo-1- [6- (trifluoromethyl) pyridin-3-yl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazen-1-I -1,2-diolate, O2-{(3R)-2-оксо-1-[3-(1H-пиразол-1-ил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -2-oxo-1- [3- (1H-pyrazol-1-yl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-methylamino) diazene-1 i-1,2-diolate, O2-[(3R)-1-(4-метилфенил)-2-оксопирролидин-3-ил]-1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (4-methylphenyl) -2-oxopyrrolidin-3-yl] -1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(3-фторфенил)-2-оксопирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (3-fluorophenyl) -2-oxopyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-yl-1,2-diolate, O2-{(3R)-2-оксо-1-[3-(1H-1,2,3-триазол-1-ил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -2-oxo-1- [3- (1H-1,2,3-triazol-1-yl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N methylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(5-цианопиридин-2-ил)-2-оксопирролидин-3-ил] 1-(N-трет-бутил-N-метиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (5-cyanopyridin-2-yl) -2-oxopyrrolidin-3-yl] 1- (N-tert-butyl-N-methylamino) diazen-1-y-1,2 diolate O2-{(3R)-2-оксо-1-[4-(трифторметил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -2-oxo-1- [4- (trifluoromethyl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2 diolate O2-[(3R)-1-(3-метилфенил)-2-оксопирролидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (3-methylphenyl) -2-oxopyrrolidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate, O2-[(3R)-1-(5-хлорпиридин-3-ил)-2-оксопирролидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (5-chloropyridin-3-yl) -2-oxopyrrolidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2 diolate O2-{(3R)-2-оксо-1-[3-(1H-пиразол-1-ил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -2-oxo-1- [3- (1H-pyrazol-1-yl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-ethylamino) diazene-1 i-1,2-diolate, O2-[(3R)-1-(5-метилпиридин-3-ил)-2-оксопирролидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (5-methylpyridin-3-yl) -2-oxopyrrolidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2 diolate O2-[(3R)-1-(3,4-диметилфенил)-2-оксопирролидин-3-ил] 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - [(3R) -1- (3,4-dimethylphenyl) -2-oxopyrrolidin-3-yl] 1- (N-tert-butyl-N-ethylamino) diazen-1-yl-1,2-diolate , O2-{(3R)-2-оксо-1-[5-(трифторметил)пиридин-3-ил]пирролидин-3-ил} 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат илиO 2 - {(3R) -2-oxo-1- [5- (trifluoromethyl) pyridin-3-yl] pyrrolidin-3-yl} 1- (N-tert-butyl-N-ethylamino) diazen-1-I -1,2-diolate or O2-{(3R)-2-оксо-1-[3-(1H-1,2,3-триазол-1-ил)фенил]пирролидин-3-ил} 1-(N-трет-бутил-N-этиламино)диазен-1-ий-1,2-диолат,O 2 - {(3R) -2-oxo-1- [3- (1H-1,2,3-triazol-1-yl) phenyl] pyrrolidin-3-yl} 1- (N-tert-butyl-N ethylamino) diazen-1-yl-1,2-diolate, или его фармацевтически приемлемую соль.or a pharmaceutically acceptable salt thereof. 20. Фармацевтическая композиция, содержащая соединение по п.1 и фармацевтически приемлемый носитель.20. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier. 21. Фармацевтическая композиция, содержащая соединение по п.19 и фармацевтически приемлемый носитель.21. A pharmaceutical composition comprising a compound according to claim 19 and a pharmaceutically acceptable carrier. 22. Фармацевтическая композиция, содержащая соединение по п.19, диуретическое средство и фармацевтически приемлемый носитель.22. A pharmaceutical composition comprising a compound according to claim 19, a diuretic agent and a pharmaceutically acceptable carrier. 23. Способ лечения гипертензии у пациента, который включает введение пациенту терапевтически эффективного количества композиции по п.20. 23. A method of treating hypertension in a patient, which comprises administering to the patient a therapeutically effective amount of a composition according to claim 20.
RU2013124814/04A 2010-10-29 2011-10-25 HETEROCYCLIC DERIVATIVES OF DIAZENIUM DIOLATE RU2013124814A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40801210P 2010-10-29 2010-10-29
US61/408,012 2010-10-29
US201161549821P 2011-10-21 2011-10-21
US61/549,821 2011-10-21
PCT/US2011/057641 WO2012058203A1 (en) 2010-10-29 2011-10-25 Diazeniumdiolate heterocyclic derivatives

Publications (1)

Publication Number Publication Date
RU2013124814A true RU2013124814A (en) 2014-12-10

Family

ID=45994356

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013124814/04A RU2013124814A (en) 2010-10-29 2011-10-25 HETEROCYCLIC DERIVATIVES OF DIAZENIUM DIOLATE

Country Status (11)

Country Link
US (1) US9108920B2 (en)
EP (1) EP2632255B1 (en)
JP (1) JP2013540817A (en)
KR (1) KR20130143042A (en)
CN (1) CN103347385A (en)
AU (1) AU2011320595A1 (en)
BR (1) BR112013009389A2 (en)
CA (1) CA2814752A1 (en)
MX (1) MX2013004739A (en)
RU (1) RU2013124814A (en)
WO (1) WO2012058203A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3350B1 (en) * 2011-03-07 2019-03-13 Merck Sharp & Dohme Heterocyclic derivatives containing primary amino groups and diazeniumdiolates
US9272987B2 (en) 2011-05-02 2016-03-01 Merck Sharp & Dohme Corp. Diazeniumdiolate cyclohexyl derivatives
WO2015109014A1 (en) * 2014-01-14 2015-07-23 Euclises Pharmaceuticals, Inc. No-releasing nonoate(oxygen-bound)chromene conjugates
US20220098134A1 (en) * 2019-06-12 2022-03-31 East China University Of Science And Technology Antihypertensive polyol compound and derivative thereof
CN110934865A (en) * 2019-12-06 2020-03-31 牡丹江医学院 Pharmaceutical composition for preventing and treating hemodialysis hypotension and application thereof
CN111808091B (en) * 2020-07-02 2021-11-23 长沙天赐生物医药科技有限公司 Diazeniumdiolate Schiff base copper complex, preparation method and biological activity

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3443998A1 (en) * 1984-12-01 1986-06-05 Boehringer Mannheim Gmbh, 6800 Mannheim AMINO-PROPANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (en) 1988-12-09 1990-06-13 Hoechst Ag ENZYME-INFRINGING DERIVATIVES OF DIPEPTIDES, METHOD FOR THE PRODUCTION THEREOF, METHODS CONTAINING THEM AND THEIR USE
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
JP3190340B2 (en) * 1991-09-24 2001-07-23 アメリカ合衆国 Oxygen-Substituted Derivatives of Nucleophiles-Nitric Oxide Adducts as Nitric Oxide Donor Prodrugs
US5614656A (en) 1994-11-14 1997-03-25 Mitsubishi Jukogyo Kabushiki Kaisha Colliding G simulation apparatus
US20050137191A1 (en) 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
US5807847A (en) 1996-06-04 1998-09-15 Queen's University At Kingston Nitrate esters
JP4856295B2 (en) 1997-07-03 2012-01-18 アメリカ合衆国政府 Novel nitric oxide releasing amidine-derived diazeniumdiolate and its composition
EP1305285B1 (en) 2000-07-25 2007-05-16 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
WO2002060388A2 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AU2003234510A1 (en) 2002-05-07 2003-11-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
US6949530B2 (en) 2002-07-18 2005-09-27 The United States Of America As Represented By The Department Of Health And Human Services Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same
WO2004020408A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
JP4340232B2 (en) 2002-08-29 2009-10-07 メルク エンド カムパニー インコーポレーテッド Indoles having anti-diabetic activity
US20050065194A1 (en) 2003-01-16 2005-03-24 Geetha Shankar Methods of treating conditions associated with an Edg-2 receptor
EP1587535A4 (en) 2003-01-17 2010-02-24 Merck & Co Inc Title of the invention n-cyclohexylaminocarbonyl benzenesulfonamide derivatives
FR2902428B1 (en) * 2006-06-15 2008-08-15 Servier Lab NOVEL DIAZENIUMDIOLATE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
AR069340A1 (en) 2007-11-26 2010-01-13 Merck & Co Inc ANGIOTENSIN II RECEIVER ANTAGONISTS
FR2924713B1 (en) * 2007-12-11 2010-01-29 Servier Lab NOVEL DIAZENIUMDIOLATE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
EP2244575B1 (en) 2008-01-24 2013-07-17 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
WO2011100384A1 (en) * 2010-02-12 2011-08-18 Merck Sharp & Dohme Corp. Diazeniumdiolate cyclopentyl derivatives
WO2011146371A1 (en) * 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Diazeniumdiolate cyclohexyl derivatives
JO3350B1 (en) * 2011-03-07 2019-03-13 Merck Sharp & Dohme Heterocyclic derivatives containing primary amino groups and diazeniumdiolates
US9272987B2 (en) * 2011-05-02 2016-03-01 Merck Sharp & Dohme Corp. Diazeniumdiolate cyclohexyl derivatives

Also Published As

Publication number Publication date
EP2632255A1 (en) 2013-09-04
US9108920B2 (en) 2015-08-18
AU2011320595A1 (en) 2013-06-06
BR112013009389A2 (en) 2017-10-31
JP2013540817A (en) 2013-11-07
EP2632255A4 (en) 2014-07-23
CN103347385A (en) 2013-10-09
EP2632255B1 (en) 2017-06-21
KR20130143042A (en) 2013-12-30
US20130289003A1 (en) 2013-10-31
CA2814752A1 (en) 2012-05-03
MX2013004739A (en) 2013-07-02
WO2012058203A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
RU2013124814A (en) HETEROCYCLIC DERIVATIVES OF DIAZENIUM DIOLATE
RU2013143028A (en) Thiazolylphenylbenzenesulfonamide derivatives as kinase inhibitors
RU2506257C2 (en) Substituted pyrrolidine-2-carboxamides
JP2006500348A5 (en)
RU2008141509A (en) MGLUR5 MODULATORS 1
CA2575003A1 (en) Potassium channel inhibitors
RU2000128036A (en) AMIDINUM COMPOUNDS
RU2015106787A (en) SUBSTITUTED PYRROLES ACTIVE AS KINASE INHIBITORS
RU2006127575A (en) COMPOUND OF TRIAZOLE AND THEIR APPLICATION AS ANTAGONISTS OF A METABOTROPIC GLUTAMATE RECEPTOR
RU2007120519A (en) Aryl-substituted benzimidazole derivative
JP2012522056A5 (en)
RU2013151174A (en) SUBSTITUTED PYRIMIDINYLPYRROLES, ACTIVE AS KINASE INHIBITORS
RU2006141320A (en) NEW COMPOUNDS
RU2009126624A (en) 2- (PIPERIDIN-4-IL) -4-PHENOXY-OR Phenylinopyrimidine Derivatives as Non-nucleoside Inhibitors of Reverse Transcriptase
JP2014511869A5 (en)
JP2018530591A5 (en)
RU2009115830A (en) Pyridinecarboxamides as 11-Beta-HSD1 Inhibitors
JP2012522053A5 (en)
RU2006127572A (en) POLYHETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS ANTAGONISTS OF A METABOTROPIC GLUTAMATE RECEPTOR
JP2012528166A5 (en)
RU2009147733A (en) Pyridylpiperidine Orexin Receptor Antagonists
AR083240A1 (en) SOLID COMPOSITIONS FOR TREATMENT OF HCV INFECTIONS (HEPATITIS C)
RU2013157374A (en) INDAZOLE AND PYROROLOPYRIDINE DERIVATIVE AND ITS PHARMACEUTICAL USE
RU2008126391A (en) DERIVATIVES OF 1,5-SUBSTITUTED INDOL-2-ILAMID
RU2006127573A (en) TETRAZOL COMPOUNDS AND THEIR APPLICATION AS ANTAGONISTS OF A METABOTROPIC GLUTAMATE RECEPTOR

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150317